XML 39 R23.htm IDEA: XBRL DOCUMENT
v3.20.2

Revenues (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2020
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenues | The following table disaggregates our product sales by product and geographic region and disaggregates our royalty, contract and other revenues by geographic region (in millions):
|  | Three Months Ended June 30, 2020 |  |  |  |  |  |  |  | Three Months Ended June 30, 2019 |  |  |  |  |  |
|  | U.S. |  | Europe |  | Other Locations |  | Total |  | U.S. |  | Europe |  | Other Locations |  | Total
Product sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Atripla |  | $ | 95 |  |  | $ | 5 |  |  | $ | 3 |  |  | $ | 103 |  |  | $ | 122 |  |  | $ | 26 |  |  | $ | 4 |  |  | $ | 152 |
Biktarvy |  | 1,350 |  |  | 153 |  |  | 101 |  |  | 1,604 |  |  | 1,023 |  |  | 73 |  |  | 20 |  |  | 1,116 |
Complera/Eviplera |  | 27 |  |  | 42 |  |  | 3 |  |  | 72 |  |  | 42 |  |  | 72 |  |  | 9 |  |  | 123 |
Descovy |  | 337 |  |  | 46 |  |  | 34 |  |  | 417 |  |  | 246 |  |  | 69 |  |  | 43 |  |  | 358 |
Genvoya |  | 646 |  |  | 109 |  |  | 61 |  |  | 816 |  |  | 733 |  |  | 177 |  |  | 70 |  |  | 980 |
Odefsey |  | 273 |  |  | 98 |  |  | 11 |  |  | 382 |  |  | 266 |  |  | 111 |  |  | 10 |  |  | 387 |
Stribild |  | 39 |  |  | 12 |  |  | 8 |  |  | 59 |  |  | 78 |  |  | 24 |  |  | 6 |  |  | 108 |
Truvada |  | 370 |  |  | 6 |  |  | 11 |  |  | 387 |  |  | 657 |  |  | 41 |  |  | 20 |  |  | 718 |
Other HIV(1) |  | 11 |  |  | 1 |  |  | 16 |  |  | 28 |  |  | 9 |  |  | 1 |  |  | 5 |  |  | 15 |
Revenue share – Symtuza(2) |  | 90 |  |  | 40 |  |  | 2 |  |  | 132 |  |  | 55 |  |  | 29 |  |  | — |  |  | 84 |
AmBisome |  | 10 |  |  | 49 |  |  | 36 |  |  | 95 |  |  | 10 |  |  | 60 |  |  | 35 |  |  | 105 |
Ledipasvir/Sofosbuvir(3) |  | 24 |  |  | 4 |  |  | 39 |  |  | 67 |  |  | 86 |  |  | 22 |  |  | 85 |  |  | 193 |
Letairis |  | 80 |  |  | — |  |  | — |  |  | 80 |  |  | 204 |  |  | — |  |  | — |  |  | 204 |
Ranexa |  | 1 |  |  | — |  |  | — |  |  | 1 |  |  | 19 |  |  | — |  |  | — |  |  | 19 |
Sofosbuvir/Velpatasvir(4) |  | 165 |  |  | 57 |  |  | 113 |  |  | 335 |  |  | 219 |  |  | 156 |  |  | 118 |  |  | 493 |
Vemlidy |  | 76 |  |  | 7 |  |  | 68 |  |  | 151 |  |  | 71 |  |  | 5 |  |  | 40 |  |  | 116 |
Viread |  | 3 |  |  | 8 |  |  | 54 |  |  | 65 |  |  | 9 |  |  | 28 |  |  | 38 |  |  | 75 |
Vosevi |  | 27 |  |  | 6 |  |  | 6 |  |  | 39 |  |  | 53 |  |  | 15 |  |  | 7 |  |  | 75 |
Yescarta |  | 95 |  |  | 56 |  |  | 5 |  |  | 156 |  |  | 99 |  |  | 21 |  |  | — |  |  | 120 |
Zydelig |  | 8 |  |  | 9 |  |  | 1 |  |  | 18 |  |  | 12 |  |  | 14 |  |  | — |  |  | 26 |
Other(5) |  | 43 |  |  | 16 |  |  | 1 |  |  | 60 |  |  | 41 |  |  | 97 |  |  | 2 |  |  | 140 |
Total product sales |  | 3,770 |  |  | 724 |  |  | 573 |  |  | 5,067 |  |  | 4,054 |  |  | 1,041 |  |  | 512 |  |  | 5,607 |
Royalty, contract and other revenues |  | 14 |  |  | 62 |  |  | — |  |  | 76 |  |  | 19 |  |  | 58 |  |  | 1 |  |  | 78 |
Total revenues |  | $ | 3,784 |  |  | $ | 786 |  |  | $ | 573 |  |  | $ | 5,143 |  |  | $ | 4,073 |  |  | $ | 1,099 |  |  | $ | 513 |  |  | $ | 5,685 |
|  | Six Months Ended June 30, 2020 |  |  |  |  |  |  |  | Six Months Ended June 30, 2019 |  |  |  |  |  |
|  | U.S. |  | Europe |  | Other Locations |  | Total |  | U.S. |  | Europe |  | Other Locations |  | Total
Product sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Atripla |  | $ | 176 |  |  | $ | 12 |  |  | $ | 10 |  |  | $ | 198 |  |  | $ | 255 |  |  | $ | 42 |  |  | $ | 26 |  |  | $ | 323 |
Biktarvy |  | 2,762 |  |  | 334 |  |  | 201 |  |  | 3,297 |  |  | 1,762 |  |  | 121 |  |  | 26 |  |  | 1,909 |
Complera/Eviplera |  | 51 |  |  | 89 |  |  | 8 |  |  | 148 |  |  | 86 |  |  | 134 |  |  | 18 |  |  | 238 |
Descovy |  | 700 |  |  | 107 |  |  | 68 |  |  | 875 |  |  | 479 |  |  | 137 |  |  | 84 |  |  | 700 |
Genvoya |  | 1,258 |  |  | 260 |  |  | 122 |  |  | 1,640 |  |  | 1,461 |  |  | 370 |  |  | 164 |  |  | 1,995 |
Odefsey |  | 542 |  |  | 225 |  |  | 24 |  |  | 791 |  |  | 548 |  |  | 217 |  |  | 19 |  |  | 784 |
Stribild |  | 73 |  |  | 29 |  |  | 10 |  |  | 112 |  |  | 145 |  |  | 42 |  |  | 17 |  |  | 204 |
Truvada |  | 753 |  |  | 14 |  |  | 26 |  |  | 793 |  |  | 1,208 |  |  | 74 |  |  | 42 |  |  | 1,324 |
Other HIV(1) |  | 14 |  |  | 3 |  |  | 19 |  |  | 36 |  |  | 20 |  |  | 2 |  |  | 10 |  |  | 32 |
Revenue share – Symtuza(2) |  | 162 |  |  | 78 |  |  | 4 |  |  | 244 |  |  | 97 |  |  | 53 |  |  | — |  |  | 150 |
AmBisome |  | 28 |  |  | 108 |  |  | 78 |  |  | 214 |  |  | 18 |  |  | 117 |  |  | 63 |  |  | 198 |
Ledipasvir/Sofosbuvir(3) |  | 77 |  |  | 15 |  |  | 87 |  |  | 179 |  |  | 203 |  |  | 49 |  |  | 166 |  |  | 418 |
Letairis |  | 163 |  |  | — |  |  | — |  |  | 163 |  |  | 401 |  |  | — |  |  | — |  |  | 401 |
Ranexa |  | 9 |  |  | — |  |  | — |  |  | 9 |  |  | 174 |  |  | — |  |  | — |  |  | 174 |
Sofosbuvir/Velpatasvir(4) |  | 476 |  |  | 179 |  |  | 244 |  |  | 899 |  |  | 449 |  |  | 310 |  |  | 225 |  |  | 984 |
Vemlidy |  | 149 |  |  | 14 |  |  | 124 |  |  | 287 |  |  | 136 |  |  | 9 |  |  | 72 |  |  | 217 |
Viread |  | 7 |  |  | 19 |  |  | 79 |  |  | 105 |  |  | 21 |  |  | 42 |  |  | 84 |  |  | 147 |
Vosevi |  | 60 |  |  | 17 |  |  | 10 |  |  | 87 |  |  | 98 |  |  | 31 |  |  | 9 |  |  | 138 |
Yescarta |  | 198 |  |  | 93 |  |  | 5 |  |  | 296 |  |  | 189 |  |  | 27 |  |  | — |  |  | 216 |
Zydelig |  | 16 |  |  | 21 |  |  | 1 |  |  | 38 |  |  | 23 |  |  | 29 |  |  | 1 |  |  | 53 |
Other(5) |  | 85 |  |  | 34 |  |  | 4 |  |  | 123 |  |  | 77 |  |  | 117 |  |  | 8 |  |  | 202 |
Total product sales |  | 7,759 |  |  | 1,651 |  |  | 1,124 |  |  | 10,534 |  |  | 7,850 |  |  | 1,923 |  |  | 1,034 |  |  | 10,807 |
Royalty, contract and other revenues |  | 31 |  |  | 110 |  |  | 16 |  |  | 157 |  |  | 41 |  |  | 114 |  |  | 4 |  |  | 159 |
Total revenues |  | $ | 7,790 |  |  | $ | 1,761 |  |  | $ | 1,140 |  |  | $ | 10,691 |  |  | $ | 7,891 |  |  | $ | 2,037 |  |  | $ | 1,038 |  |  | $ | 10,966 |
____________________ |
(1) | Includes Emtriva and Tybost.
(2) | Represents our revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland UC.
(3) | Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.
(4) | Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.
(5) | Includes Cayston, Hepsera and Sovaldi.
Revenues from Major Customers | The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a percentage of total revenues):
|  | Three Months Ended |  |  |  | Six Months Ended |  |
|  | June 30, |  |  |  | June 30, |  |
|  | 2020 |  | 2019 |  | 2020 |  | 2019
AmerisourceBergen Corp. |  | 21 | % |  | 20 | % |  | 21 | % |  | 20 | %
Cardinal Health, Inc. |  | 23 | % |  | 21 | % |  | 23 | % |  | 21 | %
McKesson Corp. |  | 23 | % |  | 20 | % |  | 22 | % |  | 20 | %

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer. + References No definition available. + Details
Name: | us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration